Abstract
ABSTRACT Purpose Concurrent radio-chemotherapy has been recommended as a standard therapy in patients with upper esophageal carcinoma which is not suitable for surgery. Although INT 0123 trial indicated that the 5-fluorouracil (5-FU) plus cisplatin (DDP) combined with radiotherapy was the initial strategy, the optimal management of upper esophageal carcinoma remains undetermined. This study was conducted to evaluate the effectiveness and safety of intensity-modulated radiotherapy (IMRT) and concurrent paclitaxel plus cisplatin (TP regimen) for upper esophageal carcinoma. Materials and methods 36 patients of upper esophageal carcinoma were retrospectively analyzed. Patients were treated with IMRT (median 60 Gy) combined with concurrent TP regimen chemotherapy. The Kaplan-Meier analysis was performed in statistical analysis. Toxicities were recorded according to the NCI CTC version 3.0. Results 36 patients aged 43-73 years (median 57 years). The median follow-up period was 14.0 months. The 1-year and 2-year survival rates were 83.3% and 42.8%, respectively. The median progression-free survival (PFS) time and overall survival (OS) time were 12.0 (95% CI 8.6-15.4 months) and 18.0 months (95% CI 14.2-21.8 months), respectively. Grade 3 neutropenia, radiation-induced esophagitis and radiodermatitis were observed in 5 (13.9%), 3 (8.3%) and 8 (22.2%) patients, respectively. There were two treatment-related deaths due to esophageal perforation and hemorrhea. Conclusions For those patients with upper esophageal carcinoma, IMRT combined with concurrent TP regimen chemotherapy was an effective treatment. However, special attention should be paid to the occurrence of perforation and hemorrhea. Disclosure All authors have declared no conflicts of interest.
Highlights
Methods36 patients of upper esophageal carcinoma were retrospectively analyzed
The incidence of esophageal carcinoma is increasing in the world as well as China
To be included in our analysis, patients needed to meet the following criteria: All patients had a histologically proven esophageal carcinoma; tumor was located in the cervical or thoracic upper esophagus without visceral metastasis by esophagogastroduodenoscopy, esophagography and computed tomography (CT scan) at the time of diagnosis; they were firstly treated with intensity-modulated radiotherapy (IMRT) and concurrent TP regimen without surgery
Summary
36 patients of upper esophageal carcinoma were retrospectively analyzed. Patients were treated with IMRT (median 60 Gy) combined with concurrent TP regimen chemotherapy. The Kaplan-Meier analysis was performed in statistical analysis. Toxicities were recorded according to the NCI CTC version 3.0. Results: 36 patients aged 43–73 years (median 57 years). The median follow-up period was 14.0 months. The 1-year and 2-year survival rates were 83.3% and 42.8% respectively. The median progression-free survival (PFS) time and overall survival (OS) time were 12.0 (95% CI: 7.8–16.2 months) and 18.0 months (95% CI: 9.9–26.1 months), respectively. Grade 3 neutropenia, radiation-induced esophagitis and radiodermatitis were observed in 5 (13.9%), 3 (8.3%) and 8 (22.2%) patients respectively. There were two treatment-related deaths due to esophageal perforation and hemorrhea
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
